Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
Issued Date
2023-01-01
Resource Type
Scopus ID
2-s2.0-85160694959
Journal Title
Economic Evaluation in Genomic and Precision Medicine
Start Page
71
End Page
86
Rights Holder(s)
SCOPUS
Bibliographic Citation
Economic Evaluation in Genomic and Precision Medicine (2023) , 71-86
Suggested Citation
Yuliwulandari R., Chaikledkaew U., Prayuni K., Zahroh H., Mahasirimongkol S., Turongkaravee S., Jittikoon J., Wattanapokayakit S., Patrinos G.P. Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions. Economic Evaluation in Genomic and Precision Medicine (2023) , 71-86. 86. doi:10.1016/B978-0-12-813382-8.00003-3 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82983
Title
Economic analysis of pharmacogenetics testing for human leukocyte antigen-based adverse drug reactions
Other Contributor(s)
Abstract
Adverse drug reactions (ADRs) can cause treatment interruptions as well as disability and sometimes death. Recent developments in genetics have shown that some ADRs could be avoided by using pharmacogenetic tests before treatment initiation. However, due to their novelty, many countries, especially in Asia, are yet to implement pre-emptive genetic screenings in clinical settings. Several studies have been published on the cost-effectiveness of genetics screening before treatment initiation. This chapter discusses the potential pharmacoeconomic implications of human leukocyte antigen (HLA) typing associated with some well-known and studied ADRs and the associated implementation into routine care.